Cargando…

Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer

Angiogenesis plays a critical role in the neoplastic growth, progression, and metastasis of colorectal cancer (CRC) in a process regulated by vascular endothelial growth factor (VEGF) family members and their receptors (VEGFR). Several small-molecule anti-VEGFR tyrosine kinase inhibitors (TKIs), suc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Ying, Zou, Jia-Yun, Wang, Zhe, Wang, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701622/ https://www.ncbi.nlm.nih.gov/pubmed/31496821 http://dx.doi.org/10.2147/CMAR.S215533

Ejemplares similares

Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer
por: Liu, Shuai, et al.
Publicado: (2022)

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer
por: Song, Yan, et al.
Publicado: (2021)

Previous Use of Anti-Vascular Endothelial Growth Factor Receptor Agents Decreases Efficacy of Fruquintinib in Metastatic Colorectal Cancer Refractory to Standard Therapies
por: Wang, Lei, et al.
Publicado: (2020)

Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer—a case report and literature review
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity
por: Dudani, Ajay Indur, et al.
Publicado: (2019)

Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
por: Peng, Zhi, et al.
Publicado: (2020)

Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer
por: Shu, Yefei, et al.
Publicado: (2021)

Use of antivascular endothelial growth factor for diabetic macular edema
por: Karim, Rushmia, et al.
Publicado: (2010)

Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
por: Sun, Liying, et al.
Publicado: (2021)

RIFLE: a Phase II trial of stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer
por: Wang, Kun, et al.
Publicado: (2023)

Fruquintinib beneficial in elderly patient with neoplastic pericardial effusion from rectal cancer: A case report
por: Zhang, Ying, et al.
Publicado: (2021)

Case report: PRES associated with fruquintinib in a patient with metastatic colon cancer
por: Wang, Lu, et al.
Publicado: (2023)

PD-1 inhibitor in combination with fruquintinib therapy for initial unresectable colorectal cancer: A case report
por: Zhang, Hong-Qiang, et al.
Publicado: (2022)

A multi-center effectiveness comparison study of fruquintinib with constructed external control cohort of other targeted kinase inhibitors using real-world data in third-line treatment of metastatic colorectal cancer
por: Jin, Ying, et al.
Publicado: (2022)

Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
por: Wildiers, H, et al.
Publicado: (2003)

Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor
por: Sassa, Yukio, et al.
Publicado: (2010)

The Use of Antivascular Endothelial Growth Factor Agents in the Perioperative Period in Diabetic Vitrectomy
por: Abu-Yaghi, Nakhleh E., et al.
Publicado: (2012)

Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
por: Zampros, Ilias, et al.
Publicado: (2012)

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
por: Tranos, Paris, et al.
Publicado: (2013)

Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents
por: Abtahi-Naeini, Bahareh, et al.
Publicado: (2019)

Efficacy of sintilimab and fruquintinib combination treatment in the management of microsatellite-stable metastatic colorectal cancer: a case report
por: Lin, Sen, et al.
Publicado: (2022)

Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer
por: Li, Qingli, et al.
Publicado: (2022)

Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H/pMMR Metastatic Colorectal Cancer: A Real-World Study in China
por: Gou, Miaomiao, et al.
Publicado: (2022)

HDAC4 Inhibitors as Antivascular Senescence Therapeutics
por: Huang, Chuoji, et al.
Publicado: (2022)

Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer
por: Qin, Shukui, et al.
Publicado: (2021)

Detection of K-ras Mutations in Predicting Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitor in Patients with Metastatic Colorectal Cancer
por: Li, Ze, et al.
Publicado: (2015)

QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
por: Ghatalia, P, et al.
Publicado: (2015)

Risk of Thromboembolic Events and Major Adverse Cardiovascular Events Following Antivascular Endothelial Growth Factor Therapy in Patients with Colorectal Cancer
por: Chen, Yen-Cheng, et al.
Publicado: (2022)

The Effect of Antivascular Endothelial Growth Factor on the Development of Adhesion Formation in Laparotomized Rats: Experimental Study
por: Basbug, Murat, et al.
Publicado: (2011)

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
por: Mansour, Ahmad M., et al.
Publicado: (2014)

Clinical characteristics and antivascular endothelial growth factor effect of choroidal neovascularization in younger patients in Taiwan
por: Li, Yi-Hsuan, et al.
Publicado: (2015)

Commentary: Ziv-aflibercept: An alternative antivascular endothelial growth factor agent for polypoidal choroidal vasculopathy
por: Anshuman, Kumar, et al.
Publicado: (2019)

Antivascular endothelial growth factor‐A therapy: a novel personalized treatment approach for psoriasis
por: Luengas‐Martinez, Andrea, et al.
Publicado: (2022)

Treatment for Nontype 1 Retinopathy of Prematurity by Intravitreal Injection of Antivascular Endothelial Growth Factor Drugs
por: Zhang, Haitao, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Combined argon laser photocoagulation and antivascular endothelial growth factor for management of macular polypoidal choroidal vasculopathy
por: Sen, Parveen, et al.
Publicado: (2016)

Photodynamic therapy combined with antivascular endothelial growth factor treatment for recalcitrant chronic central serous chorioretinopathy
por: Asahi, Masumi G, et al.
Publicado: (2017)

Quantitative physiological measurements to evaluate the response of antivascular endothelial growth factor treatment in patients with neovascular diseases
por: Hong, In Hwan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lmplsqfiqka3sej2qhfiif7i9c